Levetiracetam Tablet, Film Coated, Extended Release
Product Images NDC 69367-332

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 69367-332). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Westminster Pharmaceuticals, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Levetiracetam 01)

Chemical structure of Levetiracetam, showing its molecular arrangement including a pyrrolidone ring, an ethyl group, and an amide functional group.*

FDA Label Image

Figure 1 (Levetiracetam 02)

A bar graph comparing the percentage of patients across three groups: placebo, immediate-release levetiracetam 1,000 mg/day, and immediate-release levetiracetam 3,000 mg/day. The y-axis shows the percentage of patients from 0% to 45%. The placebo group has approximately 7.4%, the 1,000 mg/day group has 37.1%, and the 3,000 mg/day group has 39.6% of patients. The x-axis labels include patient group sizes (N=96, N=97, N=101 respectively).*

FDA Label Image

Figure 2 (Levetiracetam 03)

A bar chart depicting the percentage of patients across three groups: Placebo (N=111) at 6.3%, Immediate-release levetiracetam 1,000 mg/day (N=106) at 20.8%, and Immediate-release levetiracetam 2,000 mg/day (N=106) at 35.2%. The y-axis represents the percentage of patients, ranging from 0% to 45%.*

FDA Label Image

Figure 3 (Levetiracetam 04)

A bar chart comparing the percentage of patients between placebo and immediate-release levetiracetam 3,000 mg/day groups. The vertical axis shows percentage of patients, with placebo group at 14.4% and immediate-release levetiracetam group at 39.4%.*

FDA Label Image

Figure 4 (Levetiracetam 05)

Bar chart comparing the percentage of patients for placebo and immediate-release levetiracetam groups. The placebo group (N=97) shows 19.6% of patients, while the immediate-release levetiracetam group (N=101) shows 44.6%. The y-axis represents the percentage of patients, ranging from 0% to 45%.*

FDA Label Image

Principal Display Panel (500 mg Tablet Bottle Label)

Levetiracetam Extended-release Tablets USP 500 mg film-coated tablet label. The label states once daily dosing and includes storage instructions and container requirements. It is manufactured by ScieGen Pharmaceuticals, Inc. and labeled for Westminster Pharmaceuticals, LLC. The package contains 60 tablets with a barcode on the right side.*

FDA Label Image

Principal Display Panel (750 mg Tablet Bottle Label)

Label for Levetiracetam Extended-release Tablets, USP 750 mg, film-coated, oral tablets. The label indicates once daily dosing and includes storage instructions, manufacturer information (ScieGen Pharmaceuticals, Inc.), and labeler information (Westminster Pharmaceuticals, LLC). The package contains 60 tablets and includes a barcode and NDC 69367-333-60.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.